RxDoctor Payments Data

Scott Pethke, MD

Pulmonary Disease · Augusta, GANPI 1609828094

Payments from drug & device makers

$14,241in general payments, 2019–2025

Across 631 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$3K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Sanofi$710
  • Regeneron Healthcare Solutions, Inc.$594
  • Boehringer Ingelheim$589
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$13,87497%
  • Education$3673%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,241 in reported general payments places this provider in the 75th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$179,417
Medicare patients
527
Services billed
2,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter393$339,453
Breztri AerosphereBudesonide/Glycopyr/Formoterol206$147,645
Breo ElliptaFluticasone/Vilanterol66$36,209
Ambrisentan11$31,350
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$24,740
Spiriva RespimatTiotropium Bromide17$20,673
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$14,922
SymbicortBudesonide/Formoterol Fumarate35$13,682
Spiriva HandihalerTiotropium Bromide12$9,118
Albuterol Sulfate HfaAlbuterol Sulfate205$8,438
Arnuity ElliptaFluticasone Furoate24$7,712
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$3,918
DuleraMometasone/Formoterol11$3,538
Azelastine Hcl128$3,383
Wixela InhubFluticasone Propion/Salmeterol22$2,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$2,945$408,114528 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,949$161,327241 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$589$35,59541 claims
MerckDulera$574$3,53811 claims
Teva Pharmaceuticals USA, Inc.Proair Respiclick$14$73211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →